Loading patent…
OwnerBernd Sundermann, Lars Walz +3inventors
InventorsBernd Sundermann, Lars Walz, Silke Baasner, Frank Nocken, Christoph Meyer
Estimating the term…
Disclosed herein is a solution, in particular a pharmaceutically acceptable solution, comprising icodextrin and hydroxyalkyl starch (HAS) that can be used in methods of preventing metastasis formation and/or relapse by administration to a body cavity of a subject afflicted with cancer. Also disclosed is a kit comprising icodextrin and HAS in pre-weighed amounts and a pharmaceutically acceptable means of dissolving the same. Also disclosed is a device comprising a pharmaceutically acceptable solution and means for administering the same.
A pharmaceutically acceptable solution comprising icodextrin and hydroxyalkyl starch (HAS), wherein said icodextrin is present at a concentration of from 1 to 7.5% (w/v) and wherein said HAS is present at a concentration of from 1 to 15% (w/v).
-10. (canceled)
A kit comprising icodextrin and HAS in pre-weighed amounts and a pharmaceutically acceptable means of dissolving the same.
A pharmaceutically acceptable solution comprising icodextrin and hydroxyalkyl starch at a total concentration in the range of from 1 to 20% (w/v), wherein the weight ratio of the icodextrin relative to the hydroxyalkyl starch is in the range of from 0.05:1 to 5:1.
A method for preventing metastasis formation and/or relapse in a subject afflicted with cancer, the method comprising administering a pharmaceutically acceptable solution comprising icodextrin at a concentration of from 1% to 7.5% (w/v) and hydroxyalkyl starch (HAS) at a concentration of from 1% to 15% (w/v) to a body cavity of the subject.
(canceled)
A composition comprising icodextrin and hydroxyalkyl starch (HAS).
Dependencies are inferred from the claim text.